Latest news with #QuanterixCorporation
Business Wire
2 days ago
- Business
- Business Wire
Quanterix to Present at Goldman Sachs Global Healthcare Conference
BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the Goldman Sachs 46 th Annual Global Healthcare Conference in Miami, Florida on Monday, June 9 th, at 1:20 p.m. ET. Quanterix will also host one-on-one meetings with institutional investors during the conference. Webcast Information The live webcast presentation can be accessed from the Investors section of the company's website at A replay of the webcast will be available for a limited period following the conference. To learn more about Quanterix, visit To learn more about Quanterix's Simoa ® technology, visit About Quanterix From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa ® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,400 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at or follow us on Twitter and LinkedIn.
Yahoo
13-05-2025
- Business
- Yahoo
Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates
Quanterix Corporation (QTRX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.26 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 23.19%. A quarter ago, it was expected that this company would post a loss of $0.27 per share when it actually produced a loss of $0.30, delivering a surprise of -11.11%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Quanterix , which belongs to the Zacks Medical - Products industry, posted revenues of $30.33 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 8.99%. This compares to year-ago revenues of $32.07 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Quanterix shares have lost about 50.3% since the beginning of the year versus the S&P 500's decline of -3.8%. While Quanterix has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Quanterix: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.38 on $30.83 million in revenues for the coming quarter and -$1.62 on $138.32 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 33% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Medtronic (MDT), is yet to report results for the quarter ended April 2025. The results are expected to be released on May 21. This medical device company is expected to post quarterly earnings of $1.58 per share in its upcoming report, which represents a year-over-year change of +8.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Medtronic's revenues are expected to be $8.81 billion, up 2.6% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Quanterix Corporation (QTRX) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Business Wire
05-05-2025
- Business
- Business Wire
Quanterix To Report First Quarter 2025 Financial Results on May 12, 2025
BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Monday, May 12, 2025, at 4:30 p.m. E.T., to discuss its first quarter 2025 financial results. Quanterix will issue a press release regarding its first quarter 2025 financial results prior to the conference call on Monday, May 12, 2025, after the market closes. The press release will be posted on the Quanterix website at To listen to the live conference call, investors can dial (800) 715-9871 or (646) 307-1963 and enter conference ID 7353673. Interested investors can also access the live webcast from the News & Events page within the Investors section of the Quanterix website at An archived webcast replay will be available on the Company's website for one year. About Quanterix From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa ® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,200 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at or follow us on Twitter and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'may,' 'will,' 'expect,' 'plan,' 'anticipate,' 'estimate,' 'intend' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix' expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix' actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix' filings with the U.S. Securities and Exchange Commission, including the 'Risk Factors' sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Yahoo
01-04-2025
- Health
- Yahoo
Quanterix Showcases Innovation Powered by Simoa® at AD/PD with Customer Research and New Dried Blood Spot Extraction Kit
Simoa® technology highlighted in more than 80 posters and oral presentations demonstrating its impact on neurodegenerative disease research BILLERICA, Mass., April 01, 2025--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the inclusion of a new dried blood spot extraction (DBS) kit as part of their industry-leading Simoa® assay kits at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) in Vienna, Austria. This new extraction kit enables researchers to measure low-concentration biomarkers from dried blood spots using a more cost-effective and less invasive method. Current Alzheimer's and neurodegenerative disease tests often require complex sample handling, repeated collections, and offer limited accessibility, particularly in remote or resource-limited settings, due to their reliance on venous blood draws. To address this, Quanterix, leveraging research from its collaboration with the DROP-AD Project at the University of Gothenburg, has developed a downstream DBS extraction kit that includes buffers and a sample preparation protocol, enabling accurate and sensitive measurement of neuro biomarkers from a DBS matrix. Validation studies show that DBS samples from two different devices tested with Simoa ALZpath p-Tau 217 and the Simoa extraction kit demonstrated correlation to venous in simulated CSF spiked samples of 0.75 to 0.86. This advancement lays critical groundwork for the development of scalable, minimally invasive diagnostic tools that can be deployed more broadly and equitably across populations. "Our new dried blood spot (DBS) extraction kit represents a major step forward in making biomarker testing more accessible," said Masoud Toloue, PhD, Chief Executive Officer of Quanterix. "By simplifying sample collection, DBS has the potential to expand participation in Alzheimer's research and clinical trials—especially among under-represented populations. This advancement will deepen our ability to understand the disease and its progression across diverse communities." Additionally, Quanterix's Simoa platform will be featured in over 80 posters, presentations, and sessions at AD/PD, demonstrating its significant role in advancing neurodegenerative disease research. For a full list of research available at AD/PD, please visit AD/PD's event website. About Quanterix From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,200 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at View source version on Contacts Media Contact:Marissa Klaassen(978) 488-1854media@ Investor Relations Contact:Joshua Young(508) 846-3327ir@
Associated Press
19-02-2025
- Business
- Associated Press
Neurogen Biomarking Announces Global Agreement with Quanterix for Use of Blood Biomarker Assay in its Patient-Initiated Blood Test to Support Early Detection of Dementia and Mild Cognitive Impairment Due to Alzheimer's Disease
CHICAGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Neurogen Biomarking, the world's first ecosystem for memory and thinking concerns announced today that they have entered into an exclusive agreement to use Quanterix Corporation's antibody technology to measure a specific blood biomarker that serves as an early indicator of dementia and Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD). Quanterix Corporation is a company fueling scientific discovery through ultrasensitive biomarker detection. The agreement gives Neurogen Biomarking exclusive rights to commercialize Quanterix's ultrasensitive technology in direct-to-consumer testing in the United States, Europe, and pan-Asia. 'Neurogen Biomarking's agreement with Quanterix brings us one step closer to shifting the current standard of care paradigm for detection of Mild Cognitive Impairment and dementia due to Alzheimer's by giving people easier access to clinically validated blood biomarker technology,' said Dr. Rany Aburashed, Chief Executive Officer and Founder, Neurogen Biomarking. 'Our driving force is to solve the issue of delayed detection and ultimately diagnosis by empowering patients in a responsible, scientifically and clinically controlled scalable ecosystem while also guiding them every step of the way in their brain health journey.' Neurogen Biomarking's care ecosystem includes an easy-to-use at-home blood biomarker collection test that can measure phosphorylated tau 217 (P-tau217), a specific marker for Alzheimer's disease pathology and MCI, using Quanterix's highly sensitive technology. The patient-initiated platform also provides streamlined telehealth appointments with board-certified neurologists, offering health education and a complete Brain Health Plan with actionable next steps for personalized care. 'It is Quanterix's ultrasensitive technology that made it possible to test for AD pathology in the blood. For over a decade, Quanterix has been a crucial player in this space, and we are very pleased that their cutting-edge technology is part of Neurogen Biomarking's ecosystem,' said Dr. Elisabeth Thijssen, Chief Scientific Officer, Neurogen Biomarking. 'There is a robust body of literature that shows that P-tau217 levels in blood correlate strongly with Alzheimer's disease pathology and disease progression, supporting its use as a reliable biomarker.' 1,2 Neurogen Biomarking's platform will be commercially available in early Q2 2025 for anyone eligible with memory and thinking challenges and for people concerned about symptoms that may be associated with AD. About Neurogen Biomarking An estimated 6.9 million Americans aged 65 and older were living with Alzheimer's dementia in 2024.3 Additionally, studies estimate that the prevalence of dementia and MCI is up to 22% of Americans over 65 which translates into approximately 13 million people.4 Studies reveal that MCI is underdiagnosed with average detection rates reportedly at 8% of people over 65. Patients with memory and thinking concerns often express them first to their primary care physician and then are referred to a neurologist. According to studies patients can wait from 45 to 50 months for appointment from the time they schedule an appointment with a primary care physician to seeing a neurologist.5 The current standard of care typically delays diagnosis of AD by many years which for some patients is too late for medical interventions. Neurogen Biomarking is dedicated to supporting early detection of Alzheimer's disease and Mild Cognitive Impairment. Founded by award-winning neurologist, Dr. Rany Aburashed and guided by world-renowned brain health experts, Neurogen Biomarking is on a mission to empower anyone with thinking, memory and neurological concerns with the tools, education, and motivation needed to access advanced, personalized care. To learn more visit LinkedIn. Media Contacts: For Neurogen Biomarking -or- Susan Reilly Reilly Connect [email protected] References Photos accompanying this announcement are available at:
